GET DAILY SIGNALSOraSure Technologies (OSUR) Posts Revenue Growth in Q3 as Turnaround Gains Momentum
Key Takeaways
- Total net revenue rose 14% year over year to $30.9 million, with sequential growth of 1%, marking another step in the company's return to growth.
- Diagnostics revenue climbed 16% to $16.8 million, while Sample Management Solutions revenue jumped 21% to $12.5 million.
- GAAP (Generally Accepted Accounting Principles) gross margin expanded to 45.2% from 43.5% a year earlier, and the operating loss narrowed to $13.0 million from $16.1 million.
- The company reported a net loss of $13.1 million, or $0.19 per diluted share, roughly in line with the prior-year quarter.
- Management guided to fourth-quarter 2026 revenue of $30.0 million to $32.0 million, implying continued momentum.
- OraSure ended the quarter with $148 million in cash and cash equivalents and no debt, supporting its innovation and acquisition strategy.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
- Discover Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.
Why the Results Matter
OraSure Technologies' third-quarter 2026 earnings represent a clear step forward in its ongoing transformation. Following what management called a transition year in 2025, the company is now showing top-line growth paired with better margins. These developments are worth watching because they indicate whether the focus on decentralized diagnostics is producing sustainable results. Revenue increases across both Diagnostics and Sample Management Solutions, combined with gross margin improvement, point to progress even while the firm invests in its pipeline, including the Sherlock platform and products like Sickle SCAN.
Quarterly Performance Breakdown
For the three months ended September 30, 2026, OraSure Technologies reported total net revenues of $30.9 million. That figure reflects a 14% increase from $27.1 million in the same period last year and a 1% sequential rise. Core revenue, excluding COVID-19 and discontinued lines, also reached $30.9 million and grew 14% year over year.
Diagnostics revenue advanced 16% to $16.8 million, and Sample Management Solutions revenue rose 21% to $12.5 million. GAAP gross margin improved to 45.2% from 43.5% in the prior-year quarter, reflecting operational gains. The GAAP operating loss narrowed to $13.0 million from $16.1 million. The company recorded a net loss of $13.1 million, or $0.19 per diluted share, compared with a net loss of $13.7 million, or $0.19 per diluted share, a year earlier. Results exceeded analyst expectations on the bottom line. Initial commercial orders were noted for the Colli-Pee Dx device and the OraQuick Ebola 2.0 test. Management expects fourth-quarter revenue in the $30.0 million to $32.0 million range.
Market Response and Outlook
Shares reacted in measured fashion to the release, holding relatively steady as investors balanced the revenue growth and margin progress against ongoing losses. The 14% top-line increase and smaller operating loss suggest restructuring efforts are delivering results and supporting confidence in the long-term plan. At the same time, the firm remains unprofitable while funding innovation, and attention remains on whether growth can continue into 2027 and whether new products can speed the path to profitability. I also checked this using Tickeron’s AI Screener to compare performance against peers.
Key Areas to Watch Going Forward
Fourth-quarter guidance of $30.0 million to $32.0 million indicates management anticipates the growth trend to persist through year-end. Investors will want to monitor whether gross margins can keep expanding toward the long-term target of 50% adjusted. Several potential catalysts stand out, including regulatory and commercial progress on the InteliQuick CT/NG test on the Sherlock platform and the Colli-Pee Dx device. Early orders are encouraging, yet wider adoption will hinge on approvals and customer uptake.
Internationally, OraSure is broadening its offerings beyond HIV testing, with Sickle SCAN expansion in Africa and the OraQuick Ebola 2.0 test. Independent studies and regional guidance could shape demand. The $148 million cash position and debt-free balance sheet provide room for further acquisitions, though R&D spending will likely keep near-term profits under pressure. Focus remains on revenue trends, margin movement, and product launch timing as the company targets its 2027 objectives. From what I see, the balance sheet strength gives management useful flexibility here.
Tickeron AI Tools for Research
In my analysis of names like OSUR, I often turn to Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and AI signals. It helps surface relevant ideas without manual effort and supports comparing opportunities across sectors. I’ve found it particularly useful when tracking turnaround stories and evaluating how individual companies stack up against industry benchmarks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OSUR sees MACD Histogram crosses below signal line
OSUR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 36 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for OSUR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 15 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OSUR as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
OSUR moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OSUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
OSUR broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where OSUR advanced for three days, in 176 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 101 of 138 cases where OSUR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.747) is normal, around the industry mean (4.964). P/E Ratio (-4.986) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.390) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.195) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating fairly steady price growth. OSUR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OSUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of oral fluid specimen collection devices
Industry PharmaceuticalsOther
Advertisement